2-氯-5-苯基吡嗪 | 25844-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-5-苯基吡嗪
• 英文名称: 2-Chloro-5-phenyl-pyrazine
• 英文别名: 2-Chlor-5-phenyl-pyrazin；2-Chloro-5-phenylpyrazine
• CAS: 25844-73-9
• 化学式: C₁₀H₇ClN₂
• mdl: MFCD03268585
• 分子量: 190.632
• InChiKey: IKWXPYFPNVAWJY-UHFFFAOYSA-N

物化性质

• 熔点：
  97-98 °C(Solv: hexane (110-54-3))
• 沸点：
  296.8±35.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Chloro-5-Phenylpyrazine
: MNO000115
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Toxic if swallowed.
Causes serious eye damage.
Precautionary statement(s)
Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 190,63 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Chloro-5-Phenylpyrazine
Acute Tox. 3; Eye Dam. 1; <= 100 %
H301, H318
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Chloro-5-Phenylpyrazine
T, R25R41 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (2-Chloro-5-Phenylpyrazine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (2-Chloro-5-Phenylpyrazine)
IATA: Toxic solid, organic, n.o.s. (2-Chloro-5-Phenylpyrazine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
T Toxic
R25 Toxic if swallowed.
R41 Risk of serious damage to eyes.
Further information
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-5-苯基吡嗪 在 18-冠醚-6 、 四甲基氯化铵 、 cesium fluoride 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以93%的产率得到2-fluoro-5-phenylpyrazine
  参考文献：
  名称：

  协同催化实现杂芳基氯化物和芳基三氟甲磺酸酯的亲核氟化

  摘要：

  芳基和杂芳基氟化物正日益成为制药和农用化学品中的主要基序，但在自然和日用化学品中均很少见。结果，迫切需要开发温和的，成本有效的和可扩展的氟化方法。合成芳基氟化物的最直接途径是通过卤化物交换“ halex”反应，但是条件，成本和原子经济性阻止了大规模生产过程中大多数可用的方法。我们报告了一种新的方法，该方法利用18冠6醚和四甲基氯化铵的协同作用来催化访问四甲基氟化铵的反应性，并在温和的条件下实现易于操作的卤代氟化。

  DOI：

  10.1021/acs.joc.0c02845
• 作为产物：
  描述：

  2-苯基吡嗪 在 马来酸酐 、 氢氧化钾 、 五氯化磷 、 双氧水 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 2-氯-5-苯基吡嗪
  参考文献：
  名称：

  Ohta, Akihiro; Watanabe, Tokuhiro; Akita, Yasuo, Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 1061 - 1067

  摘要：

  DOI：

文献信息

• Studies on pyrazines. 35. An improved synthesis of bromopyrazines from hydroxypyrazines
  作者：Nobuhiro Sato、Nobuhiko Narita

  DOI：10.1002/jhet.5570360334

  日期：1999.5

  The synthesis of bromopyrazines from hydroxypyrazines was successfully effected by the procedure via trimethylsilyloxypyrazines, the sequence of which proceeds under mild conditions and does not require the isolation of intermediate.

  通过三甲基甲硅烷基氧基吡嗪的方法成功地从羟基吡嗪合成了溴吡嗪，其顺序在温和的条件下进行并且不需要分离中间体。
• Direct Conversion of Haloarenes to Phenols under Mild, Transition-Metal-Free Conditions
  作者：Patrick S. Fier、Kevin M. Maloney

  DOI：10.1021/acs.orglett.6b00876

  日期：2016.5.6

  as the hydroxide source via a novel SNAr reaction/Lossen rearrangement sequence. Notably, these reactions employ inexpensive and air-stable reagents, require no special handling, occur under mildly basic conditions, and form products in high yields in the presence of electrophilic and protic functionality. The utility of this methodology is demonstrated by the high-yielding hydroxylation of two base-sensitive

  已经开发了一种高产且实用的从缺电子的卤代芳烃和杂芳烃合成苯酚的方法。该产品是由乙酰氧肟酸作为通过新S中的氢氧化物源形成Ñ氩反应/洛森重排反应序列。值得注意的是，这些反应使用廉价且空气稳定的试剂，不需要特殊的处理，在温和的碱性条件下发生，并且在亲电子和质子官能团存在下以高收率形成产物。这种方法的实用性通过两种对碱敏感的复杂底物的高产羟基化得到证明。
• INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK
  申请人：PFIZER INC.

  公开号：US20130267493A1

  公开（公告）日：2013-10-10

  The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

  本发明涉及激活5'-腺苷单磷酸活化蛋白激酶（AMPK）的吲哚和吲唑化合物的化学式（I）。该发明还包括含有这些化合物的药物组合物以及治疗或预防通过激活AMPK改善的疾病、症状或疾病的方法。
• Anticoccidials. V. Synthesis and anticoccidial activity of 2(1H)-pyrazinone 4-oxide derivatives.
  作者：MITSUHIKO MANO、TAKUJI SEO、TOSHINORI HATTORI、TATSUHIKO KANEKO、KINICHI IMAI

  DOI：10.1248/cpb.28.2734

  日期：——

  A series of 1-, 3-, 5- and 6-substituted 2(1H)-pyrazinone 4-oxides were synthesized and tested for anticoccidial activity. Of the compounds tested, 1-(β-D-ribofuranosyl)-(22), 1-(2, 3, 5-tri-O-benzoyl-β-D-ribofuranosyl)-(21) and 1-(2, 3, 5-tri-O-acetyl-β-D-ribofuranosyl)-2(1H)-pyrazinone 4-oxides (24) showed high activity.

  合成了一系列1-、3-、5-和6取代的2(1H)-吡咯啉酮4-氧化物，并测试其抗球虫活性。在测试的化合物中，1-(β-D-核糖苷)-(22)、1-(2, 3, 5-三-O-苯甲酰-β-D-核糖苷)-(21)和1-(2, 3, 5-三-O-乙酰-β-D-核糖苷)-2(1H)-吡咯啉酮4-氧化物(24)显示出较高的活性。
• Azetidines
  申请人：Dack Kevin Neil

  公开号：US20080280877A1

  公开（公告）日：2008-11-13

  The invention relates to EP2 antagonist azetidines of formula (I) wherein Ar, R 1 , X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids, to intermediates useful in their synthesis, and to compositions containing them.

  这项发明涉及到式（I）的EP2拮抗剂氮杂环丁烷，其中Ar、R1、X和Z如本文所定义，其在医学上的应用，特别是在子宫内膜异位症和/或子宫肌瘤的治疗中的应用，以及其合成中有用的中间体，以及含有它们的组合物。